Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

SOM230: a new therapeutic modality for Cushing's disease

Lewis, Ian, Schmid, Herbert, Kneuer, Rainer, Hoyer, Daniel, Silva, Antonio, Weckbecker, Gisbert, Bruns, Christian and Pless, Janos (2014) SOM230: a new therapeutic modality for Cushing's disease. Chimia, 68 (7-8). pp. 483-484. ISSN 0009-4293


A rational drug design approach involving transposition of functional groups from SRIF into a reduced size cyclohexapeptide template has led to the discovery of SOM230, a novel, stable cyclohexapeptide somatostatin mimic which exhibits unique high affinity binding to human somatostatin receptors (sst1-5). This unique receptor subtype binding profile, in particular the exceptional high affinity binding to sst5, led to SOM230 being approved by EMEA and FDA in 2012 as the first effective pituitary directed therapeutic modality for Cushing's disease.

Item Type: Article
Date Deposited: 01 Dec 2017 00:45
Last Modified: 25 Jan 2019 00:46


Email Alerts

Register with OAK to receive email alerts for saved searches.